Semaglutide is the established, approved GLP-1 medicine; retatrutide is the experimental triple agonist generating the biggest weight-loss headlines. The mechanistic gap is wide: semaglutide acts on one receptor (GLP-1), while retatrutide acts on three (GIP, GLP-1 and glucagon). Early retatrutide data show larger average weight loss than semaglutide — but semaglutide is a proven, prescribable product, and retatrutide is not yet approved.
At a glance
| Semaglutide | Retatrutide | |
|---|---|---|
| Drug class | Single GLP-1 agonist | Triple GIP + GLP-1 + glucagon agonist |
| Brand names | Ozempic, Wegovy, Rybelsus | None (investigational) |
| FDA status | Approved | Investigational — not approved |
| Reported trial weight loss | ~15% (phase 3) | ~24% at 48 weeks (phase 2) |
| Receptors engaged | One (GLP-1) | Three (GIP, GLP-1, glucagon) |
| Availability | Prescription medicine | Clinical trials only |
| Evidence maturity | Extensive completed trials | Earlier-stage data |
The bottom line
Bottom line: Retatrutide's early numbers are larger, but semaglutide is a finished, approved, widely-used medicine with a deep evidence base, while retatrutide remains investigational and unavailable outside trials. This is a comparison between a proven product and a promising candidate — not two interchangeable options.
Frequently asked questions
Is retatrutide better than semaglutide?
Early trials suggest retatrutide produces greater average weight loss (~24% vs ~15%), but it is investigational and its data are less mature. Semaglutide is approved, available, and extensively studied.
How many hormone systems does each drug target?
Semaglutide targets one receptor (GLP-1). Retatrutide targets three (GIP, GLP-1 and glucagon), which may explain its larger reported weight-loss effect.
Can I get retatrutide by prescription?
No. Retatrutide is not FDA-approved and is available only through clinical trials. Semaglutide is available by prescription. Unregulated 'retatrutide' products are research chemicals of unknown quality.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. Peer-reviewed study
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. Peer-reviewed study
- Chao AM, Tronieri JS, Amaro A, et al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023. Peer-reviewed study
- Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021. Peer-reviewed study
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. Peer-reviewed study
- Tan HC, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022. Peer-reviewed study
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023. Peer-reviewed study
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP/GLP-1/glucagon receptor agonist, in people with type 2 diabetes: a randomised phase 2 trial. Lancet. 2023. Peer-reviewed study
- Katsi V, Koutsopoulos G, Fragoulis C, et al. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025. Peer-reviewed study
- Abdul-Rahman T, Roy P, Ahmed FK, et al. The power of three: Retatrutide's role in modern obesity and diabetes therapy. Eur J Pharmacol. 2024. Peer-reviewed study
- Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026. Peer-reviewed study
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. Peer-reviewed study